Transgene SA (EPA:TNG)
0.7550
-0.0020 (-0.26%)
Apr 24, 2026, 3:16 PM CET
Transgene Revenue
In the year 2025, Transgene had annual revenue of 7.21M EUR with 13.49% growth. Transgene had revenue of 2.63M in the half year ending December 31, 2025, a decrease of -16.13%.
Revenue
7.21M
Revenue Growth
+13.49%
P/S Ratio
28.76
Revenue / Employee
49.72K
Employees
145
Market Cap
207.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.21M | 857.00K | 13.49% |
| Dec 31, 2024 | 6.35M | -1.55M | -19.58% |
| Dec 31, 2023 | 7.90M | -2.44M | -23.63% |
| Dec 31, 2022 | 10.34M | -6.90M | -40.00% |
| Dec 31, 2021 | 17.24M | 7.67M | 80.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Genfit | 65.43M |
| Fermentalg | 13.38M |
| Adocia | 12.88M |
| Innate Pharma | 9.01M |
| Sensorion | 5.81M |
| MaaT Pharma | 4.52M |
Transgene News
- 3 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 3 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 3 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 3 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 3 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire
- 3 years ago - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 - Business Wire